INCB086550

• CAT Number: I044532
• CAS Number: 2230911-59-6
• Molecular Formula: C41H39N7O4
• Molecular Weight: 693.79
• Purity: ≥95%
• Synonyms: (3R)-1-[[7-cyano-2-[3-[3-[[3-[[(3R)-3-hydroxypyrrolidin-1-yl]methyl]-1,7-naphthyridin-8-yl]amino]-2-methylphenyl]-2-methylphenyl]-1,3-benzoxazol-5-yl]methyl]pyrrolidine-3-carboxylic acid
• InChI: InChI=1S/C41H39N7O4/c1-24-32(5-3-7-34(24)40-46-36-17-26(15-30(18-42)38(36)52-40)20-47-13-10-29(22-47)41(50)51)33-6-4-8-35(25(33)2)45-39-37-28(9-12-43-39)16-27(19-44-37)21-48-14-11-31(49)23-48/h3-9,12,15-17,19,29,31,49H,10-11,13-14,20-23H2,1-2H3,(H,43,45)(H,50,51)/t29-,31-/m1/s1
• InChIKey: QARLNMDDSQMINK-BVRKHOPBSA-N
• SMILES: CC1=C(C=CC=C1C2=NC3=CC(=CC(=C3O2)C#N)CN4CC[C@H](C4)C(=O)O)C5=C(C(=CC=C5)NC6=NC=CC7=CC(=CN=C76)CN8CC[C@H](C8)O)C

INCB086550（Cat No.:I044532）is an investigational small-molecule inhibitor developed by Incyte that selectively targets the fibroblast growth factor receptors FGFR1, FGFR2, FGFR3, and FGFR4. These receptor tyrosine kinases are frequently altered in various cancers through mutations, amplifications, or fusions, leading to uncontrolled cell growth and survival. INCB086550 blocks FGFR signaling, thereby inhibiting tumor proliferation and angiogenesis. It is being evaluated in clinical trials for cancers such as cholangiocarcinoma, urothelial carcinoma, and endometrial cancer with FGFR alterations. Its oral bioavailability and selectivity make it a promising candidate in precision oncology.